$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
SAN DIEGO, March 29, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day on Thursday, April 6, 2017, from 8:30 a.m. to 11:30 a.m. EDT (5:30 a.m. to 8:30 a.m. PDT) in New York City. Jeffrey Stein, Ph.D., president and chief executive officer, and other members of the Cidara management team, will provide a comprehensive corporate update. In addition, notable infectious disease experts will discuss their perspectives on the anti-infective space.
Interested parties may access a live audio webcast and slides of the presentations on the investor section of Cidara’s website at www.cidara.com beginning at 8:30 a.m. EDT. An archive of the webcast will be available shortly after the event and can be viewed at the same link for a limited time.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through a Phase 2 study and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT: Robert H. Uhl Westwicke Partners, LLC Managing Director (858) 356-5932 [email protected] MEDIA CONTACT: Christy Curran Sam Brown Inc. (615) 414-8668 [email protected]
